Mitochondrial antiviral-signaling protein
Mitochondrial antiviral-signaling protein (MAVS), also known as IPS-1, VISA, and Cardif, is a key protein involved in the innate immune response to viral infections. MAVS is encoded by the MAVS gene in humans and plays a crucial role in the immune system by mediating antiviral signaling pathways.
Structure[edit]
MAVS is a mitochondrial membrane protein that contains an N-terminal caspase recruitment domain (CARD), a proline-rich region, and a C-terminal transmembrane domain. The CARD domain is essential for the interaction with other CARD-containing proteins, such as RIG-I and MDA5, which are cytoplasmic sensors of viral RNA.
Function[edit]
MAVS is pivotal in the activation of the type I interferon response. Upon recognition of viral RNA by RIG-I or MDA5, these sensors undergo conformational changes and interact with MAVS through CARD-CARD interactions. This interaction leads to the formation of a signaling complex on the mitochondrial membrane, which subsequently activates downstream signaling pathways, including the NF-κB and IRF3 pathways. The activation of these pathways results in the production of type I interferons and other pro-inflammatory cytokines, which are essential for the antiviral response.
Role in Disease[edit]
Mutations or dysregulation of MAVS can lead to impaired antiviral responses and increased susceptibility to viral infections. Additionally, some viruses have evolved mechanisms to inhibit MAVS function, thereby evading the host immune response. Research has also suggested a potential link between MAVS and certain autoimmune diseases, where an overactive immune response may be detrimental.
Interactions[edit]
MAVS interacts with several proteins involved in the antiviral signaling pathway, including:
These interactions are crucial for the propagation of the antiviral signal and the subsequent activation of the immune response.
Research and Therapeutic Potential[edit]
Given its central role in antiviral immunity, MAVS is a target of interest for therapeutic interventions aimed at enhancing antiviral responses or modulating immune activity in autoimmune diseases. Ongoing research is focused on understanding the detailed mechanisms of MAVS signaling and its regulation.
See also[edit]
References[edit]
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
Medical weight loss NYC | Affordable GLP-1 injections NYC | Budget GLP-1 weight loss shots Philadelphia | New Jersey medical weight loss | NYC medical weight loss | Philadelphia medical weight loss | Sleep clinic NYC | W8MD's Philadelphia GLP-1 doctor | Weight loss prescriptions NYC
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian